Lupin Eyes Another Mirabegron Launch Amid Ongoing Litigation
The Firm Reported A 16% YoY Sales Increase, With ‘Robust Growth’ Across All Key Regions
With a clear focus on complex products, Lupin sets out its launch plans for the year ahead, while battling ongoing litigation over some of its generics.
